GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lucy Scientific Discovery Inc (NAS:LSDI) » Definitions » Sloan Ratio %

Lucy Scientific Discovery (Lucy Scientific Discovery) Sloan Ratio % : 0.00% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Lucy Scientific Discovery Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Lucy Scientific Discovery's Sloan Ratio for the quarter that ended in Dec. 2023 was 0.00%.

Warning Sign:

When sloan ratio (-50.76)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Dec. 2023, Lucy Scientific Discovery has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Lucy Scientific Discovery Sloan Ratio % Historical Data

The historical data trend for Lucy Scientific Discovery's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucy Scientific Discovery Sloan Ratio % Chart

Lucy Scientific Discovery Annual Data
Trend Jun21 Jun22 Jun23
Sloan Ratio %
- -73.49 -50.76

Lucy Scientific Discovery Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lucy Scientific Discovery's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Lucy Scientific Discovery's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucy Scientific Discovery's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lucy Scientific Discovery's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Lucy Scientific Discovery's Sloan Ratio % falls into.



Lucy Scientific Discovery Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Lucy Scientific Discovery's Sloan Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Sloan Ratio=(Net Income (A: Jun. 2023 )-Cash Flow from Operations (A: Jun. 2023 )
-Cash Flow from Investing (A: Jun. 2023 ))/Total Assets (A: Jun. 2023 )
=(-8.988--4.266
--0.266)/8.779
=-50.76%

Lucy Scientific Discovery's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-11.301--5.924
--0.423)/4.287
=-115.56%

Lucy Scientific Discovery's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -4.106 (Mar. 2023 ) + -2.577 (Jun. 2023 ) + -1.998 (Sep. 2023 ) + -2.62 (Dec. 2023 ) = $-11.30 Mil.
Lucy Scientific Discovery's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -2.035 (Mar. 2023 ) + -1.861 (Jun. 2023 ) + -1.288 (Sep. 2023 ) + -0.74 (Dec. 2023 ) = $-5.92 Mil.
Lucy Scientific Discovery's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -0.3 (Mar. 2023 ) + 0 (Jun. 2023 ) + -0.123 (Sep. 2023 ) + 0 (Dec. 2023 ) = $-0.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lucy Scientific Discovery  (NAS:LSDI) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Lucy Scientific Discovery has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Lucy Scientific Discovery Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Lucy Scientific Discovery's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucy Scientific Discovery (Lucy Scientific Discovery) Business Description

Traded in Other Exchanges
N/A
Address
301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6
Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.
Executives
Richard D Nanula director, officer: Executive Chairman C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Charles B Nemeroff director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Paul Abramowitz director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brian Zasitko officer: Chief Financial Officer C/O LUCY SCIENTIFIC DISCOVERY, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Scott M. Reeves director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Christopher Mcelvany director, officer: President and CEO C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Livio Susin director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brittany Kaiser director C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Assad J Kazeminy officer: Chief Scientific Officer C/O LUCY SCIENTIFIC, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6